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ORIGINAL ARTICLE
Integrating Clinical Phenotype and Gene Expression
Data to Prioritize Novel Drug Uses
H Paik1,2, B Chen1,2, M Sirota1,2, D Hadley1,2 and AJ Butte1,2*
Drug repositioning has been based largely on genomic signatures of drugs and diseases. One challenge in these efforts lies
in connecting the molecular signatures of drugs into clinical responses, including therapeutic and side effects, to the
repurpose of drugs. We addressed this challenge by evaluating drug-drug relationships using a phenotypic and molecular-
based approach that integrates therapeutic indications, side effects, and gene expression profiles induced by each drug.
Using cosine similarity, relationships between 445 drugs were evaluated based on high-dimensional spaces consisting of
phenotypic terms of drugs and genomic signatures, respectively. One hundred fifty-one of 445 drugs comprising 450 drug
pairs displayed significant similarities in both phenotypic and genomic signatures (P value< 0.05). We also found that similar
gene expressions of drugs do indeed yield similar clinical phenotypes. We generated similarity matrixes of drugs using the
expression profiles they induce in a cell line and phenotypic effects.
CPT Pharmacometrics Syst. Pharmacol. (2016) 5, 599–607; doi:10.1002/psp4.12108; published online 14 November 2016.
Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE
TOPIC?
 A central premise in the computational approach to
drug repositioning is that similar compounds induce
similar clinical responses. Although, in clinical practice,
drug administration is generally conducted based on
phenotypic efficacy, whereas the computational predic-
tion of novel drug indications has been based largely
on genomic signatures of the drugs.
WHAT QUESTION DID THIS STUDY ADDRESS?
 Systematically, can we determine similar drugs by
integrating drug-associated gene expressions and known
clinical phenotypes? Using cosine similarity approach,
we have compared the drug-drug similarity in terms of
phenotypic terms and gene expression signatures. In
overall, when a pair of drug showed significant similarity
based on gene expression signatures, the pair also pre-
sented phenotypic similarity. In addition, we identified a
promising drug repositioning candidate, thioridazine
(anti-schizophrenia drug) for metastasis of breast cancer,
by integration of drug associated gene expressions and
clinical phenotypes.
WHAT THIS STUDY ADDS TO OUR KNOWLEDGE
 Using cosine-similarity, relationships between drugs
were evaluated based on high-dimensional spaces,
consisting of phenotypic terms of drugs and genomic
signatures, respectively. Clinical phenotype or gene
expression signatures of drugs are significantly nonin-
dependent; similar gene expressions of drugs do
indeed yield similar clinical phenotypes.
HOW MIGHT THIS CHANGE DRUG DISCOVERY,
DEVELOPMENT, AND/OR THERAPEUTICS?
 This work is a generalized method that paves the
way to leveraging drug-induced gene expression pro-
files and term-based phenotypic understandings for
drug repositioning.
Drug repositioning is the process of identifying novel indica-
tions for approved drugs. This methodology in drug discov-
ery has several advantages over novel drug discovery and
development. For example, rising development costs, high
attrition rates during clinical trials, and greater concerns
about drug safety1–3 are among the many hurdles that hin-
der the success of novel disease therapies. However, drug
repositioning has still not fully matured, and it generally relies
on an unorganized process based largely on serendipity. For
example, sildenafil (Viagra; Pfizer) was originally for cardio-
vascular indications and it was repositioned to erectile dys-
function because of side effects in human volunteers.4
Precise prediction of new indications could shorten devel-
opment time and identify more potential uses for a single
drug. Computational approaches to discover new indica-
tions or biological targets have been applied to generate
novel repositioning opportunities.5–8 Specifically, guilt-by-
association is a well-known approach that explores similar
drug-drug or disease-disease pairs. These studies exploited
relationships between drugs and target genes to infer novel
drug indications.
Many studies have analyzed either molecular-level states
induced by disease or drugs, or phenotypic profiling from
human individuals with the goal of drug repositioning.9–11 For
example, the Connectivity Map elucidates relationships
between small molecule drugs and diseases.12 In previous
works, we proposed a method based on a guilt-by-
association approach to predict new ones13 and integrated
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clinical phenotypes from electronic medical records.14 In this
way, identification of similar drugs by considering diverse
aspects, including molecular genomic profiles15 and pheno-
types, such as clinical observations, indications, and side
effects of a drug, can lead to repositioning. Meanwhile,
exploring drug-associated phenotypes (i.e., side effects and
therapeutic indications) are promising for drug repositioning;
however, large-scale integration between phenotypic and
genomic information-derived drug repositioning remains as
challenging issues and has been rarely attempted.16,17
To date, drug-associated phenotypic information has
been used as either side effects or therapeutic indications
without directionality.9,10,18 An example of directionality is
that sildenafil reduced (downregulated) erectile dysfunction
as an indication, and rarely induced (upregulated) head-
aches as an adverse effect. Typical application of drug-
associated phenotypes has mainly focused on side effects
as Boolean values (i.e., has side effect “X” or not).
Although the object of drug administration is to reverse dis-
ease phenotypes, using directional relationships between
drug and phenotype signatures has not been reported thus
far. Moreover, by connecting gene expression signatures to
clinical phenotypes, such as efficacies (indications) and
side effects, a systematic evaluation for drug-drug relation-
ships remains as a central promise for drug repurpose.
In this study, using cosine-similarity measures, we com-
pared drug-drug relationships in terms of molecular and
clinical levels, including gene expression signatures in a
single cell line and known phenotypic terms in human indi-
viduals. Whereas in text mining field, the cosine-similarity
score is a well-known method to quantify similarity between
a pair of corpus, such as a set of clinical phenotypic terms
(e.g., side effects) for drugs, also has been examined to
detect gene-based similarity of drugs.19,20 We applied the
cosine-similarity score as a generalized measurement to
determine relationships between drugs based on sparse
and high dimensional feature vectors, such as corpus of
phenotypic terms for drugs and identified gene signatures.
Interestingly, 151 drugs had significant similarities in both
phenotypic and gene expression profiles, revealing novel
drug-repositioning candidates.
METHODS AND DATA
Data
Drug-associated phenotypic terms. We retrieved phenotype
characteristics of drugs involving side effects and approved
therapeutic indications using the side effect resource
(SIDER2)21 and US Food and Drug Administration Adverse
Event Reporting System (FAERS).22 We extracted side
effects listed on labels and adverse effects that had been
reported but were not listed on labels. In addition, we
obtained approved indications of drugs from the DrugBank23
and the US Food and Drug Administration Orange Book.24
The Unified Medical Language System25 and MetaMap26
were used to systematically conduct a concept-based inte-
gration9 of terms for side effects, drug indications, and
names of drugs.
Gene expression profiles under drug treated conditions.
The Connectivity Map (latest date of download: 19 August
2014)12 was used to prepare expression profiles under vari-
ous drug-treated conditions.
Drug-associated phenotypic terms. Phenotypic terms (or
concepts) are commonly represented by multidimensional
feature vectors for each object (i.e., drug).27 We described
j-th drug using a vector of phenotypic terms Tdj as follows:
Tdj5 ðt1;j ; t2;j ; . . . ti ;j ; . . . ; tn;jÞ (1)
Here, tij grades the associations between i-th phenotypic
term and drug j (1 i n). The association value between
phenotype and drug is very different by prevalence of phe-
notypic terms across drugs and the source of phenotypic
information. For example, there are highly abundant side
effects, such as nausea, and therapeutic indications from
drug label information, such as a migraine headache. In
addition, we also determined directionality of association
between phenotypic terms and drugs, such as positive and
negative relationships by every k-th dataset. For example,
the term “dizziness” for drug p in the side-effect database
has a positive relationship, whereas the same term for drug
q in therapeutic indication resources has a negative rela-
tionship. To account for heterogeneity in different data sour-
ces (i.e., side effect and therapeutic indication databases),
we normalized Dk(Tij) to measure the strength of an associ-
ation between phenotype i and drug j by overall co-
occurrence of the phenotypic term i across all drugs in k-th
dataset. The relationship between phenotype i and drug j
was determined by k-th database as an index value Ik(Tij);
21 for negative relationship and 11 for positive relation-
ship. By integrating phenotypic term values from various
data sources, an association value of tij for drug j was
defined using the following equation:
tij5
1
K
XK
k51
Ik Tij
 Dk Tij
 
Dk nið Þ (2)
In Eq. 2, K denotes the number of integrated data sources
and Dk(ni) denotes the number of drugs where the term i
appears in the k-th data source. Dk(Tij) is a Boolean value (0
or 1) due to our utilized data sources. For Ik(Tij), a database
for the side effects of drugs (SIDER21 and FAERS22) has a
positive index of 11, whereas a source for therapeutic indi-
cation (DrugBank23 and the US Food and Drug Administra-
tion Orange Book24) has a negative relation index of 21.
Drug-associated gene expression signatures. In terms of
the expression signature, we also described j-th drug using
a vector of expression signature Gdj:
Gdj5 ðg1;j ; g2;j ; . . . gp;j ; . . . gmjÞ (3)
Here, gpj denotes expression signatures of p-th gene under j-
th drug-treated conditions. Based on z-score transformed
expression signatures, we identified differentially expressed
genes by comparing nontreated array expressions using the
P value of the t test with adjusting the false discovery rate
using the Benjamini-Hochberg procedure for multiple compar-
isons (FDR <0.1). The detailed methods for our z-score
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based methods have been described.28 In summary, we nor-
malized gene expression signatures using z-score transfor-
mation, and then filtered differentially expressed genes
comparing nondrug treated conditions via t test (FDR <0.1).
In this study, we utilized drug-associated expression profiles
with at least two arrays per cell line and drug in the Connec-
tivity Map. With the genes selected from this work, we utilized
mean values of z-score transformed expression values for
our cosine-similarity analysis procedure. Because the Con-
nectivity Map profiled expressions using five cell lines (MCF7,
HL60, ssMCF7, PC4, and SKMEL5), we independently ana-
lyzed drug-associated Gdj in each cell line. The Connectivity
Map has a number of arrays and drug-treated conditions for
each cell line: 3,213 arrays for 1,294 drugs in MCF7 cells,
1,848 arrays for 1,182 drugs in PC3 cells, 1,281 arrays for
1,078 drugs in HL60 cells, 23 arrays for 16 drugs in ssMCF7
cells, and 22 arrays for 17 drugs in SKMEL5 cells.
Cosine similarity of drugs. Cosine-similarity analysis is a
widely used method for quantifying similarities between two
concepts using high-dimensional vectors. We analyzed the
similarity of drugs using various features, including known phe-
notypic terms, and profiled expression signatures. The gene
expression and phenotypic term-based similarity between the
vectors of two drugs x and y were calculated as follows:
cos Tdx ; Tdy
 
5
P
i tix tiyffiffiffiffiffiffiffiffiffiffiP
i t
2
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q ffiffiffiffiffiffiffiffiffiffiP
i t
2
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q (4)
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Eq. 4 quantifies the similarity of drugs using associated
phenotypic terms, and Eq. 5 quantifies the similarity of
identical drug pairs based on gene expression signatures
from the Connectivity Map. Cosine-similarity scores range
from 21 (opposite symptoms or gene expression patterns)
to 0 (no common symptoms or gene expression patterns)
to 11 (identical symptoms or expression patterns). Pairwise
comparisons between phenotype and gene signature based
cosine-similarity scores were completed after quantile nor-
malization process. We conducted random permutation
analysis to evaluate statistical significance.
RESULTS
Overview of drug relationship analysis
We extracted drugs and phenotypic terms associated with
them by integrating 1,513 therapeutic indications of 1,473
drugs (DrugBank), >13,000 side effects of >5,000 drugs
(SIDER2 and FAERS) and therapeutic equivalence evalua-
tions about 473 indications of 49,515 drugs (US Food and
Drug Administration Orange Book).21–24 The Unified Medi-
cal Language System25 and MetaMap26 were used to sys-
tematically conduct concept-based integration of various
terms for side effects and therapeutic indications from dis-
tinct resources,9 and were also used for the integration of
drug names. Table 1 shows the number of drugs we ana-
lyzed and associated phenotypes for each resource. As
described in Table 1, phenotypes of drugs comprise clinical
phenotypes, such as side effects and disease indications.
We analyzed >6,000 microarray profiles and used them
to generate drug-associated gene expression signatures
from the Connectivity Map.12 Gene expression profiles
under drug-treated conditions were independently analyzed
in five cell lines (MCF7, PC3, HL60, ssMCF7, and
SKMEL5). Because we used a t test for selecting drug-
associated gene signatures after z-score transformation of
expression profiles, we excluded >3,000 arrays with single
profiles for a drug-treated condition, and only used arrays
with at least two profiles per condition. Among them, we
excluded over 1,000 drugs and associated expression pro-
files due to absence of phenotypic terms or gene
Table 1 Summary of data used
Data level Data resources Features Number
Drug-associated clinical phenotypes SIDERa No. of drugsb
Type of associated side effectsc
996
4,492
FAERSd No. of drugsb
Type of reported side effectsc
No. of reported casesa
5,689
9,268
223,178
DrugBank No. of drugsb
Type of approved therapeutic indicationsc
1,473
1,513
FDA Orange Book No. of drugsb
Type of approved therapeutic usec
49,515
473
Integrated results No. of drugsc
No. of associated phenotype terms
1,631 (445e)
1,587
Drug-associated gene expression The Connectivity Map Total no. of drugs
Total no. of analyzed expression profiles
Cell linesg
1,309 (856f)
6,100 (3,204f)
5
FAERS, US Food and Drug Administration Adverse Event Reporting System; FDA, US Food and Drug Administration; SIDER, side effect resource.
aSIDER (sideeffects.embl.de/). bThis number was calculated by using the drug names or ingredients. cWe integrated the name of the drugs using concept identifi-
cation of drugs in the Unified Medical Language System, and prepared drug lists by integrating drugs from the Connectivity Map. dAdverse events were selected
if they had been reported in 30 cases. eNumber of drugs that have both the phenotypic terms and gene expression signatures from the Connectivity Map. fOw-
ing to the z-score based approach, drug-associated expression profiles with single array data were excluded. Finally, of 1,309 drugs and 6,100 expression profiles,
856 drugs and 3,204 expression profiles were used for further analysis. gThe five cell lines were MCF7, HL60, PC3, ssMCF7, and SKMELS.
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expression profiles. The majority of treated drugs in the
Connectivity map (759 of 1,309 drugs) were treated in
MCF7. Thereby, we mainly utilized the drug associated
gene signatures in MCF7 to compare the results of pheno-
type based drug similarity analyses. We selected the com-
mon drugs between 759 treated drugs in MCF7 and 1,631
drugs having phenotypic terms. This process left 445 drugs
with 1,587 phenotypic terms and 1,099 expression profiles
across 22,000 genes in MCF7 (Table 1).
Figure 1 shows our workflow for generating drug-drug
relationships. As described in the Methods section, we first
computed term values of clinical phenotypes, such as side
effects and disease indications, for each drug as a Boolean
in each data resource (i.e., true or false relationships
between drug A and phenotype X), and then determined
the directionalities of these relationships between drugs
and clinical phenotypes. To ensure the specificity of pheno-
typic terms, we normalized term values by overall frequen-
cies of phenotype-drug relationships, such as how many
drugs shared clinical phenotype X. Each normalized and
directional term value is identical within a data resource.
We combined associated phenotypic terms for each drug
and determined drug-associated phenotypic signatures as
a result. Next, we aggregated term values for each drug by
calculating mean scores across various phenotype resour-
ces for the drugs (Figure 1a).
Figure 1b starts with drug-drug similarity analysis via
z-score transformation of gene expression profiles under
Figure 1 Pipeline for identifying drug-drug relationships using phenotype and gene expression signatures. (a) Drug-associated hybrid
phenotypes, including side effects and therapeutic indications, were prepared via integration of multiple public resources, as noted. Direc-
tionality and normalized term values for each phenotype for each drug were determined as described in the Methods section. After aggre-
gating term values, we computed cosine similarities between drug pairs (21 or 11). (b) Data preparation and analysis procedure for
gene-signature based cosine similarity for two queried drugs. For direct comparisons of drug pairs, we transformed gene expression sig-
natures as z-scores. Drug-associated gene signatures were prepared by t test analysis (false discovery rate [FDR] <0.1). Finally, trans-
formed gene signatures for a drug consisted of high-dimensional gene spaces to analyzed cosine similarity for drug pairs.
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drug-treated and nontreated conditions in MCF7. Next, we
examined P values of t tests and used them to select
drug-associated gene expression signatures in MCF7 (FDR
<0.1), as described in the Methods section.28 Using z-
scores of selected genes in each drug-treated MCF7, our
cosine-similarity analysis quantified relationships between
drug-drug pairs. The Supplementary Data has presented
all of the normalized term values for all 445 drugs by uti-
lized data resources, including DrugBank, Orange Book,
FAERS, and SIDER2, and z-score transformed gene
expression profiles by treated drugs in MCF7 and PC3.
Using established phenotypic concepts and expression
signatures for 445 drugs in MCF7, we compared cosine-
similarity analysis to determine similarity scores for queried
drug pairs under distinct measures, such as clinical pheno-
types and gene signatures in a cell line (Figure 1a,b).
Cosine-similarity scores capture directionality of compared
objects. A score of 11 denotes identical relationships,
whereas 21 denotes opposite relationships for pairs of drugs
based on phenotypic information and gene expression. For
statistical significance of these scores, we used random
permutation methods as described (P value< 0.05).29
Landscape of drug-associated phenotypic effects and
expression profiles
By integrating drug-associated clinical phenotypic terms
from public resources, as denoted in Table 1, we produced
a bipartite network consisting of 3,218 nodes involving
1,631 drugs, 1,587 phenotypes, and 72,848 edges for sig-
nificant positive and negative relationships. Negative rela-
tionships between drugs and phenotypic terms represent
therapeutic effects of the drugs, and positive scores repre-
sent drug-induced side effects. The number of clinical phe-
notypic terms for each drug followed a power-law-like
distribution in terms of side effects and therapeutic indica-
tions (Supplementary Figure S1a–c).
We also established a network model of drugs and asso-
ciated gene signatures in MCF7 using the Connectivity
Map. As shown in Supplementary Figure S1d, 8,101
genes are differentially expressed across the effect of 759
drugs (FDR of t test <0.1), and these genes and drugs are
represented as nodes linked with 17,000 edges in MCF7
cells. Using z-score transformed gene expression signa-
tures from drug-treated and nontreated MCF7 cell lines,28
directionality of edges between drug and gene nodes was
determined (negative association5 z-score <0; positive
association5 z-score >0) and significance levels were
computed using t tests with an FDR cutoff of 0.1. As with
drug term relationships, expression and phenotypic signa-
tures of drugs can be displayed as scale-free networks
(Supplementary Figure S1d,f).
Relationships between clinical phenotypic and genetic
signature-based drug similarity
We used drug-associated gene signatures and phenotypic
term values to determine and compare the drug-drug rela-
tionships using cosine-similarity analysis. By random per-
mutation of drug-gene expression and drug-phenotypic
term value matrixes, we generated background distributions
of cosine-similarity, respectively. Although both of the
random models for gene expression and clinical phenotype-
based cosine-similarity values converged upon zero, overall
distributions were distinct (P value of t test 3.27E-03; Fig-
ure 2a). Using these random distributions, we independent-
ly evaluated statistical significances of cosine-similarity
based on phenotypic terms and gene signatures in MCF7
(P value of permutation< 0.05).
Among over 197,000 possible pairs of 445 drugs, we
used cosine similarity to identify 5,996 pairs from among
409 drugs as having similar gene signatures (3% of over
197,000 possible pairs of 445 drugs; P value of
permutation<0.05). A total of 13,468 pairs from among
437 drugs were identified as phenotypically similar drugs
(6% of over 197,000 possible pairs of 445 drugs, P value of
permutation<0.05; Figure 2b). In order to maximize the
number of comparisons between phenotypic terms and
gene signature derived drug-drug relationships, we intro-
duced liberal P values to select sets of similar drug pairs
without FDR corrections (P value<0.05). A modest fraction
(450 pairs of drugs consisting of 151 drugs) was found to
be similar in both the phenotype-based and gene-based
cosine-similarity analysis (0.2% of 197,000 comparisons;
P value of cosine similarity< 0.05). However, the P values
of binomial tests show that selecting either phenotypic or
expressional signatures based on similar drug pairs is
significantly nonindependent (P value52.61E-302;
Figure 2b). Likewise, in PC3 cell lines, we also identified
that a selection of similar drugs based on gene signatures
is associated with phenotypic similarity (P value5 5.3e-65;
Supplementary Figure S2). However, 25,752 pairs of
drugs (13% of 197,580 pairs of drugs) were identified as
similar drugs in terms of phenotype “without directionality”
(Supplementary Table S3). The identified similar drug
pairs in terms of phenotype “with directionality” (6% of over
197,000 possible pairs of 445 drugs) are a subset of these
selected drugs without directionality (Supplementary
Table S3). Interestingly, methotrexate and hydroflumethia-
zide are identified as a similar pair in term of phenotype
“without directionality” (Supplementary Table S3). Howev-
er, hydroflumethiazide is a known diuretic for liver cirrhosis
and a known side effect of methotrexate is liver cirrhosis. In
our cosine similarity of directional phenotype analysis, hydro-
flumethiazide and methotrexate are opposite pairs by the
opposite relationship with liver cirrhosis (Figure 3b). Thus, a
pair of hydroflumethiazide and methotrexate is a false-
positive result. Thereby, identification of similar drug pairs by
either nondirectional clinical phenotype or gene expression
signatures in MCF7 is selected by chance (P value of bino-
mial 0.19) due to the false-positive results from the nondirec-
tional phenotype signatures.
Figure 2c,d present the relationship of drug similarity
measures between gene-based cosine similarities and phe-
notypic term-based values in MCF7 and PC3. Interestingly,
when pairs of drug have significantly shared gene expres-
sion signatures, phenotype-based similarities have drasti-
cally increased (red arrow remarked). However, similar drug
pairs, based on the phenotypic terms, have discrete trends
for gene-based similarity measures (orange boxed regions
in Figure 2c,d). Thus, similar gene expressions of drugs
do indeed yield similar clinical phenotypes.
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Based on the shared side effects between drugs, Campil-
los et al.30 also presented a prediction of similar drugs
(1,017 pairs of drugs consisting of 424 drugs). Of these,
407 pairs of similar drugs consisting of 227 drugs are group
1, which is matched with known target shared drugs.
Among our set of similar drugs in Supplementary
Table S1 (Figure 2b; 450 pairs of drugs consisting of 151
drugs), 48 pairs of drugs comprising 24 drugs involve the
identical drugs in the group 1 predicted set of Campillos
et al.30 In total, 25% of 48 pairs (12 pairs) are matched
with the set of Campillos et al.30 Interestingly, other
unmatched 36 pairs of similar drug in our prediction identi-
fied known similar drugs in terms of clinical uses (Supple-
mentary Table S2). For example, our methods determined
that raloxifene and tamoxifene are a similar pair of drug;
these two drugs are well-known drugs for treating breast
cancer.31
By exploring established networks for drug and clinical
phenotype in Supplementary Figure S1, we identified that
421 of clinical phenotypes can be regarded as either side
effects or therapeutic effects of drugs. Meanwhile, 1,033 of
clinical phenotypes can only be regarded as side effects of
drugs. Otherwise, 133 terms have only been regarded as
therapeutic effects. In Figure 3a, we presented an example
that shared clinical phenotype between a pair of drugs in
opposite directionality. Methotrexate and hydroflumethiazide
have shared a common clinical phenotype term, liver cirrho-
sis, in opposite directionality. Liver cirrhosis is a known ther-
apeutic indication of hydroflumethiazide (i.e., negative
association; red edge in Figure 3a), whereas methotrexate
Figure 2 Comparison between phenotype and gene-signature based cosine similarity. (a) Random distributions of cosine-similarity mea-
sures using drug-phenotypic term relations (upper chart) and gene expressions (lower part) by N-permutation approach. (b) Vann dia-
gram of selected similar drug pairs by using phenotypic terms (light gray) and gene signatures in MCF7 (light green). All lists of selected
450 drugs are presented in Supplementary Table S1. Gene-signature-based cosine similarity are in red. Prednisone (blue) is an exam-
ple of disparity of phenotype and gene-based cosine-similarity analysis. Cosine similarity scores for phenotype and gene-based results
were quantile normalized for direct comparison. (c,d) Relationships between phenotype-based and gene-based cosine similarity in each
cell line (c) comparison between cosine similarity based on phenotype and gene signatures in MCF7; (d) utilized gene signatures in PC3.
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Figure 3 Evaluation of cosine-similarity measures and selected repositioning candidate. (a) Example of shared clinical phenotypes
between drugs in opposite directionality. Phenotype term “liver cirrhosis” has distinct relationships between methotrexate and hydroflu-
methiazide. (b) Comparison of cosine-similarity scores with (red) or without phenotype directionality (green). (c,d) Computed cosine
similarity between thioridazine and other drugs. Both charts were ordered in descending order by rank of gene-signature based cosine
similarity. The P values of cosine-similarity values were determined by random permutations. Drugs similar to thioridazine in phenotype
and gene-signature-based cosine similarity are red. Prednisone (blue) is an example of disparity of phenotype and gene-based cosine
similarity analysis. Cosine similarity scores for phenotype and gene-based results were quantile normalized for direct comparison.
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has positive association with liver cirrhosis (side effects of
methotrexate; blue edge in Figure 3a). With directional
associations between drugs and clinical phenotype terms,
cosine-similarity score determined hydroflumethiazide and
methotrexate as an opposite pair of drugs, although it was
identified as similar drugs without directionality information.
In Figure 3b, we compared similarities between methotrex-
ate and other 15 drugs, including hydroflumethiazide, using
clinical phenotypes with directionality (red line) and without
directionality (green line). Cosine similarities in gene expres-
sion signatures in MCF7 also identified hydroflumethiazide
and methotrexate as an opposite drug pair (blue line in Fig-
ure 3b). Our method can identify the opposite relationships
of drugs, whereas a method that compared cosine similarity
with nondirectional phenotype vectors of drugs had over-
looked the relationship. However, the contributions of utilized
resources, such as side effects and therapeutic indications,
remained unclear. Admittedly, comparing similarity results
based on each phenotype resource might determine the
benefit of the selected features. When we utilized only the
therapeutic indication or side effect resources of 445 com-
pared drugs, over 200 drugs had no associated phenotypic
terms. Therefore, imbalance of data abundance hampered
fair evaluations by the absence of identical sets.
Identification of drug repositioning candidates
The identified 450 similar drug pairs in Figure 2b shared
both clinical phenotype terms and gene expression signa-
tures. These drugs are promising repositioning pairs and are
presented in Supplementary Table S1. With stringent P val-
ues, such as P50.01 or 0.001, the majority of similar drugs
are almost the same drugs, including nortriptyline (pain med-
ication) and protriptyline (pain medication; Supplementary
Table S1). In order to explore drug-repositioning candidates,
we applied a liberal P value of 0.05. As repurposing candi-
dates among the 450 pairs of drug, we focused on pairs of
similar drugs without known common indications.
Rank of phenotype and gene-based cosine similarity of
drugs between thioridazine and 445 other drugs showed dis-
parity and partial matched trends, except in self-comparison
cases (Figure 3c,d). Based on both of the phenotypic and
gene signatures, thioridazine (antischizophrenia drug) dis-
played significant similarity with 16 drugs, including antimalarial
and anticancer drugs (Supplementary Table S1). Among 16
drugs, 11 were antipsychotic drugs, such as trifluoperzine and
pimozide (antipsychotic indications, including schizophrenia
and depression; P value of hypergeometric test: 2.3E-08). The
therapeutic potential of thioridazine as an antimicrobial agent,
including use for malaria, is supported by cell assay analysis.32
In addition, thioridazine has been cited as a promising candi-
date for cancer therapy based on cell-based analysis.33 Owing
to mitoxantrone’s anticancer indication, we suggest thiorida-
zine as a repurposing candidate for relapsed acute leukemia,
metastasis of breast cancer, and non-Hodgkin’s lymphoma.
DISCUSSION
The pharmaceutical industry is under pressure to develop
drugs at a time when costs related to validation are a major
burden. This problem is compounded by soaring costs due
to the high failure rate of de novo drug discovery; one result-
ing in a renewed interest in drug repositioning. An important
challenge to repositioning efforts lies in selecting therapeutic
areas to test drugs of interest. We have started to address
this challenge by systematically compiling drug-associated
phenotypes, including side effects and therapeutic efficacies,
as well as the transcriptomic effects of these compounds.
We used public repositories and captured 1,587 approved
drug indications and side effects, and 1,099 gene expression
profiles of 445 drugs in the MCF7 cell line.
We applied a guilt-by-association data-driven strategy to
find drug-repositioning candidates based on genomic and
phenotypic features in our results. Although the disparity in
relationship of drugs between known phenotypes (i.e., side
effects) and molecular targets is well-known,30 it depends
on the expression profiles from a cancer cell line (MCF7)
subset of compared drug pairs (0.2%), which showed that
homogeneous trends between phenotype and gene signa-
ture had derived similarity. Interestingly, identifying similar
drug pairs by either phenotype or gene signature-based
cosine-similarity analysis was significantly nonindependent
(P value of binomial test 2.61E-302). In addition, identifica-
tion of similar drug pairs by either of the nondirectional clini-
cal phenotype or gene expression signatures in MCF7 is
selected by chance (P value of binomial 0.19) due to the
false-positive results from the nondirectional phenotype sig-
natures. However, imbalance of data abundance among uti-
lized resources, such as side effects and therapeutic
indications of drugs, hampered the contributions of utilized
resources. We also compared our prediction results with
previous work that utilized the side effects of drugs without
directionality.30 Over 40% of a comparison set of drugs (12
pairs among 48 pairs consisting 24 drugs) has matched,
and unmatched similar drugs of ours cover well-known simi-
lar drugs, such as raloxifene and tamoxifen.31
As an example of the potential benefit of our approach in
the drug-repositioning task, we explored the suggested
drug relationships for thioridazine for identifying drug-
repositioning candidates. Among 16 similar drugs, 11 identi-
fied several interesting repositioning candidates for thiorida-
zine, including malaria and cancer, with previous
studies.32,33 Currently, a clinical trial for the use of thiorida-
zine for refractory acute myeloid leukemia is recruiting
(ClinicalTrials.gov: NCT02096289, phase I).
Our method demonstrates that analysis based on drug-
phenotype relations and molecular-level pharmacological
data can yield candidates for repositioning. In our previous
work, we analyzed the similarity of diseases using only
genomic signatures.28 The methods in our previous work
(z-score approach) utilized only continuous values, includ-
ing gene expressions, and it is inappropriate for indexed (or
categorical) values, such as term value of clinical pheno-
type. This study has focused on the examination of drug-
drug similarity regarding both gene expressions and clinical
phenotypes using a simple and general method.
Some limitations of our approach should be recognized.
Cosine-similarity scores were based on expression profiles
in a single cancer cell line, whereas drug-associated pheno-
types came from patients with diverse diagnoses. Thus,
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capturing drug-associated gene signatures under the rele-
vant disease conditions remains challenging. We acknowl-
edge that phenotype-based similarity analysis is biased
toward older drugs that have diverse uses with many noted
side effects. In addition, abundance of data among side
effects and therapeutic indication-associated resources are
sparse and imbalanced. Thereby, zero values of cosine simi-
larity of drugs using clinical phenotypes are substantial.
Therefore, extraction of clinical phenotypes from medical
records is the right direction of future studies. We acknowl-
edge that a case study imperfectly displayed the benefit of
directional relationships. However, a case study is a feasible
way to deliver the potential benefit of our study. We note that
there is no standard and feasible measure to evaluate the
accuracy of drug-drug relationships. In addition, except for
clinical trials, there is no systematic guideline to evaluate
drug-repositioning candidates. Admittedly, large-scale drug-
drug relationship analysis with/without directionality to priori-
tize drug-repositioning candidates and experimental validation
and then compare the success rate in clinical trials in
population-wide levels would be ideal. Nevertheless, practical
constraints probably make such a systematic study
unfeasible. However, we observed that many first-line neuro-
psychiatric drugs, such as gabapentin for epilepsy and parox-
etine for major depression, had the largest number of ranked
side effects, indicating that they may be better-targeted thera-
pies to be considered as potential first-line candidates for
neuropsychiatric disease.
Nonetheless, we believe that our method, in conjunction
with existing discovery approaches, such as clinical pheno-
type data and molecular drug signatures, will enable phar-
maceutical companies and other medical associations to
drive more testing of existing drugs and help expedite
future drug repositioning efforts.
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